Screener
Mirum Pharmaceuticals, Inc. MIRM Acquired in-process research and development
Acquired in-process research and development at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:ResearchAndDevelopmentExpenseAcquiredInProcessCost.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of sales | 30,348 | 23,421 | 59,153 | 46,439 |
| Research and development | 90,528 | 46,067 | 188,438 | 87,111 |
| Acquired in-process research and development | 16,435 | — | 742,737 | 5,000 |
| Selling, general and administrative | 81,469 | 63,286 | 177,799 | 120,992 |
| Total operating expenses | 218,780 | 132,774 | 1,168,127 | 259,542 |
| Loss from operations | (42,537) | (4,989) | (832,002) | (20,172) |
| Other income (expense): |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s acquired in-process research and development?
- Mirum Pharmaceuticals, Inc. (MIRM) reported acquired in-process research and development of $16.44M in Q2 2026.
- What does acquired in-process research and development mean?
- Acquired in-process research and development as reported by Mirum Pharmaceuticals, Inc. Common Stock.
Ask your AI about Mirum Pharmaceuticals, Inc.'s acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude